SCHEMBL4936037

SCHEMBL4936037

CCCC(Br)C(=O)c1ccccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.56
SLC6A4 P31645 1/20 0.56
SLC6A3 Q01959 1/20 0.56
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 1/20 0.40
HPGD P15428 2/20 0.39
CA2 P00918 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
F2R P25116 1/20 0.38
ELANE P08246 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4103763 0.80 PTPN1 (0.51) KMT2ATSHRMAPK1HPGDALDH1A1
SCHEMBL5313314 0.79 TAS1R3 (0.49) NPC1RAB9AKMT2ASMN1; SMN2TSHR
SCHEMBL28629683 0.77 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3ERCC5FEN1
SCHEMBL2823791 0.77 SLC6A2 (0.53) SLC6A2SLC6A3NPC1RAB9AKMT2A
SCHEMBL4935875 0.77 SLC6A2 (0.53) SLC6A2SLC6A3NPC1RAB9AKMT2A
SCHEMBL5744225 0.76 NPC1 (0.46) SLC6A2SLC6A4SLC6A3ERCC5FEN1
SCHEMBL405449 0.75 TSHR (0.50) SLC6A2SLC6A4SLC6A3ERCC5FEN1
SCHEMBL14720363 0.75 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3ERCC5FEN1
SCHEMBL2233660 0.73 HPGD (0.48) SLC6A2SLC6A4SLC6A3ERCC5FEN1
SCHEMBL10446352 0.73 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3ERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) 2008-09-25 US disclosed
EP-1670755-A4 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF HARVARD COLLEGE (US) 2007-02-28 EP disclosed
EP-1670755-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF President And Fellows of Harvard College (US) 2006-06-21 EP disclosed
WO-2005034878-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof SLC6A2, SLC6A4, SLC6A3 SLC6A2 1/4885SLC6A4 2/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.